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The candidate proto-oncogene bcl-3 encodes a protein that shares tructural features with IKB-~ and other 
proteins that bind to members of the Rel protein family. Here, we show that in contrast to the inhibitory 
activity of IKB-a, the bcl-3 gene product superactivates NF-KB p50 homodimer-mediated gene expression both 
in vivo and in vitro. BCL-3 protein can, as well, selectively associate with p50 homodimers in the presence of 
DNA containing a KB motif. These results strongly suggest hat BCL-3 can act as a transcriptional coactivator, 
acting through DNA-bound pS0 homodimers. 
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The candidate proto-oncogene bcl-3 was identified by 
the cloning of chromosomal breakpoints from chronic 
lymphocytic leukemia cells containing a t(14;19) trans- 
location (Ohno et al. 1990). bcl-3 expression is activated 
by translocation without apparent alteration of the en- 
coded protein structure. The deduced primary structure 
of BCL-3 contains seven repeats of an -30-amino-acid 
motif (ankyrin repeat) found in several other proteins 
(Nolan and Baltimore 1992). These include erythrocyte 
ankyrin, a cytoskeletal protein; yeast cell cycle regula- 
tory proteins, such as cdclO and SWI6; and the trans- 
membrane receptors notch, TAN1, and int-3. 
The closest relatives of BCL-3 are proteins that affect 
the activity and intracellular localization of NF-KB. IKB- 
oL, a protein encoded by MAD-3 cDNA (Haskill et al. 
1991), has five full copies of the ankyrin motif in a pat- 
tern very similar to that found in BCL-3 (Nolan and Bal- 
timore 1992). It inhibits the DNA binding of NF-KB and 
sequesters it in the cytoplasm (Baeuerle and Baltimore 
1988a). NF-KB is a protein of two subunits, p50 and p65, 
both of which are related in structure to the rel oncogene 
protein (Nolan and Baltimore 1992). IKB has the highest 
affinity for the p65 subunit (Baeuerle and Baltimore 
1989). Like BCL-3, the IKB-~/protein has seven ankyrin 
motifs (Inoue et al. 1992a; Liou et al. 1992). It is the 
carboxyl half of the p105 NF-KB-1 precursor of the p50 
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subunit, as well as an independent protein in some lym- 
phoid cells (Liou et al. 1992). A close relative of NF-KB-1, 
NF-KB-2 pl00, also has an IKB-~/-related carboxyl termi- 
nus (Neri et al. 1991; Schmid et al. 1991). 
BCL-3 is functionally related to, but distinct from, 
IKB-~ in that it preferentially interacts with the p50 sub- 
unit of NF-KB (Wulczyn et al. 1992) and both proteins 
colocalize to the nucleus (Nolan et al. 19931, whereas the 
primary target for IKB-c~ is the p65 subunit of NF-KB and 
the complex is found in the cytoplasm. Also, the amino 
acids flanking the ankyrin repeats of IKB-~ and BCL-3 
differ markedly. The latter, but not the former, contains 
proline-rich regions in its amino and carboxyl termini 
and a serine-rich carboxy-proximal region. Because the 
ankyrin repeat domain is implicated in protein-protein 
interactions, these unique regions might have effector 
roles in the nucleus. In previous work, however, it was 
found that BCL-3 protein produced by bacteria [Wulczyn 
et al. 1992) or insect cells (Nolan et al. 1993) inhibits the 
DNA-binding activity of NF-KB p50, suggesting that it 
has an inhibitory role. 
pS0 homodimers [KBF-1, (p50)2] are detected in the nu- 
cleus of some cells as a binding activity specific for a site 
within the major histocompatibility complex (MHC) 
class I (H-2) gene enhancer. The detection of KBF-1 and 
the expression of the H-2 gene is highly correlated (Burke 
et al. 1989; Isra61 et al. 1989). In vivo, competition ex- 
periments have demonstrated that the factor interacting 
with the H-2 KB site activates MHC gene expression 
(Baldwin and Sharp 1987; Isra61 et al. 1987). However, 
recent transient ransfection experiments using chlor- 
amphenicol acetyltransferase (CAT) as a reporter failed 
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to show significant rans-activation by cDNA-mediated 
pS0 expression (Schmid et al. 1991; Schmitz and Bae- 
uerle 1991; Beg et al. 1992). More recently, while our 
study was in progress, Franzoso et al. (1992) reported that 
BCL-3 acts as an antagonist of p50 that strongly inhibits 
KB motif-dependent CAT gene expression. 
In the following experiments, we employed a transient 
transfection system using luciferase as reporter of KB- 
regulated transcription. Contrary to the previous results 
(Schmitz and Baeuerle 1991; Franzoso et al. 1992), we 
observed that p50 activates gene expression both in vivo 
and in vitro and that BCL-3 can superactivate in a p50- 
dependent manner. Furthermore, BCL-3 protein pro- 
duced in mammalian cells associated with p50 which 
was bound to a KB oligonucleotide in vitro. These results 
strongly suggest hat BCL-3 does not function solely as 
an inhibitor but, rather, that it can act as a transcrip- 
tional coactivator for (p50)2. 
Results 
BCL-3 synergistically activates gene expression 
with p50 in vivo 
Various laboratories have reported that in cotransfection 
experiments, the p50 subunit of NF-KB activates tran- 
scription poorly from KB-driven reporter constructs 
while p65 activates well (Schmitz and Baeuerle 1991; 
Beg et al. 1992). However, we found that in vitro (p50)2 is 
an excellent ranscriptional ctivator on certain KB sites 
and that (p65)2 is not an especially good activator (Fujita 
et al. 1992). We have therefore reinvestigated the activity 
of these regulators in a cotransfection system using a 
luciferase reporter system rather than the previously uti- 
lized CAT system. Luciferase protein is detectable at 
very low levels (De Wet et al. 1987) and is intrinsically 
unstable, whereas the CAT assay is less sensitive and the 
protein is more stable. Thus, luciferase activity should 
reflect the instantaneous concentration of its mRNA 
rather than measuring the protein that accumulates over 
many hours as is assayed by CAT. 
We transfected into mouse L929 cells a luciferase re- 
porter gene along with effector constructs encoding var- 
ious NF-KB-related proteins. The reporter contained a
simple promoter from the [3 interferon (IFN-[3) gene (Fu- 
jita et al. 1987), along with three upstream KB sites. The 
KB motif studied first was that from the immunoglobulin 
K gene {IgK), which responds in vitro about equally to p50 
and p65. With increasing concentration of either effector 
plasmid, there was an increasing synthesis of luciferase 
(see Fig. 1A, bars 4 and 7; other data not shown). If the 
reporter lacked KB sites, p50 was unable to stimulate. It
is evident hat p50 is an activator of transcription on an 
IgK KB motif. 
We then investigated whether BCL-3 would affect the 
response to p50. We compared it with IKB-~, an inhibitor 
known to interact with p65. Expression of BCL-3 or IKB 
alone had little effect on reporter gene expression (Fig. 
1A). Coexpression of p50 with the reporter gave the ex- 
pected stimulation, and BCL-3 augmented that simula- 
tion further {Fig. 1A). Because Franzoso et al. {1992} had 
previously reported quite different results with the 
NTera-2 cell line--a human embryonic arcinoma cell 
that lacks endogenous NF-KB-related proteins--we x- 
amined the behavior of our reporter and expression plas- 
mids in that cell line. A similar activation of the lu- 
ciferase reporter gene by p50 was observed in these cells, 
as well as perhaps a greater BCL-3 augmentation {Fig. 
1B). In L929 cells, p65 also stimulated, but BCL-3 gave no 
augmentation a d IKB repressed the activation by either 
p50 or p65 {Fig. 1A). The opposing effects of BCL-3 and 
IKB on p50-mediated activation were particularly clearly 
demonstrated in titrations of the effector plasmid {Fig. 
1C). The inhibitory effect of IKB in vitro and in vivo to 
(p65)2 or p50/p65 is well documented (Baeuerle and Bal- 
timore 1989; Nolan et al. 1991; Beg et al. 1992), but this 
is the first demonstration that gene activation mediated 
by p50 can be inhibited by IKB under certain conditions. 
Whereas the p50-IKB interaction is not evident by mo- 
bility shift assay unless a large excess of IKB is added 
{Liou et al. 1992), this result is consistent with the find- 
ing that p50 homodimer can be coimmunoprecipitated 
(Inoue et al. 1992b) and sequestered in cytoplasm by ec- 
topic expression of IKB {Beg et al. 1992). 
Franzoso et al. {1992) used a reporter containing natu- 
ral HIV LTR in their assay and showed that this con- 
struct is activated by BCL-3 in the presence of p50 and 
p65. We tested asimilar HIV LTR luciferase construct as 
reporter {Fig. 1D). The reporter is little activated either 
by p50 or BCL-3 alone; however, it is dramatically acti- 
vated by coexpression of both. Thus, the synergism seen 
with synthetic KB constructs can be reproduced using a 
more physiological regulatory DNA sequence. 
Physiologically, p50 is processed from precursor p105 
by proteolytic removal of its carboxyl region {Blank et al. 
1991). Transfection of a p105 expression plasmid in hu- 
man kidney cell line 293 and mouse L929 cells resulted 
in an accumulation of p50 as well as its precursor, as 
evidenced by Western blotting {data not shown). Trans- 
fection of a p 105 expression plasmid into L929 cells gave 
no detectable stimulation of luciferase, but BCL-3 was 
able to activate transcription just as it could with direct 
p50 expression {Fig. 2A). This shows that physiologically 
processed p50 can participate in gene activation syner- 
gistically with BCL-3. The lack of direct activation by 
p105 could be the result of the level of p50 derived by 
cleavage. 
Our findings contrast with those reported by Franzoso 
et al. {1992). They found that coexpression of p65 is pre- 
requisite for BCL-3 to activate gene expression and in- 
terpreted the result as indicating that p65 is the true 
activator and BCL-3 acts by removing inhibitory {p50)2. 
However, in the system described here, ectopic p65 ex- 
pression is not required and expression of both p50 and 
BCL-3 are required for maximal gene expression. The 
p50 protein is not encoded as such but derives by prote- 
olysis from a p105 precursor {Blank et al. 1991), and dif- 
ferent laboratories have made different p50 constructs by 
truncating a p l05-encoding plasmid at particular places. 
In certain reports {Beg et al. 1992; Franzoso et al. 1992), 
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Figure 1. Effect of BCL-3 and IKB on KB 
motif-dependent gene activation in vivo. 
(A) L929 cells were transfected with a re- 
porter plasmid (p-55IgKLuc, 0.5 ~g) and ef- 
fector plasmids (each 0.05 gg). (1) No ef- 
fector; (2)pGDMBCL3; (3)pCDMIKB; (4) 
pCDM50; (5) pCDM50 + pCDMBCL3; 
(6) pCDM50 + pCDMIKB; (7) pCDM65; 
(8) pCDM65 + pCDMBCL3; (9) pCDM65 
+ pCDMIKB. In all of the cotransfection 
experiments, total amounts of plasmid 
were kept constant by adding the vector 
without insert. (B) NTera2 cells were 
transfected with reporter plasmid (p- 
55IgKLuc, 3 ~g) and effector plasmids ( 1 ~g 
each). Error bars represent s.E. from tripli- 
cate transfection results. (1) No effector; 
(2) pCDMBCL3; (3) pCDMS0; (4) 
pCDMS0 + pCDMBCL3. (C) L929 cells 
were transfected with p-55IgKLuc {0.5 p,g) 
and indicated amounts of pCDMBCL3 (E]) 
or pCDMIKB (0). (D) L929 cells were 
transfected with pHIVLTRLuc (0.5 ~g) and 
effector plasmids (0.05 ~g each). (1  No ef- 
fector; (2)pGDMBCL3; (3)pCDMS0; (4) 
pCDMBCL3 + pCDM50. Error bars in A, 
C, and D represent S.E. from quadrupli- 
cated transfection trials. 
pS0 was expressed from a cDNA truncated by digestion 
with the restriction enzyme XbaI to give a 503-amino- 
acid protein [p50XbaI, which directs synthesis of an ap- 
parently 60-kD polypeptide in L929 cells (T. Fujita et 
al., unpubl.)]. In our laboratory pS0 was produced from a 
plasmid truncated at an FspI site (Fujita et al. 1992) to 
produce a protein of 401 amino acids that migrates co- 
incidently with authentic p50. We compared as activa- 
tors our pS0, p50XbaI, and p52, a protein closely related 
to p50 (Fig. 2B). p50, p50XbaI, and p52, respectively, ac- 
tivated the reporter gene moderately; however, only pS0 
and p52 superactivated with BCL-3. Because p50 and 
pSOXba are accumulated in similar amounts in trans- 
fected L929 cells (data not shown), the failure of p50Xba 
to cooperate with BCL-3 is likely attributable to its ex- 
tended length, compared with that of p50. The magni- 
tude of activation by p52 and p50 was comparable in 
repeated experiments (data not shown). Thus, it is clear 
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why Franzoso et al. (1992) were unable to see synergism 
of their p50 and BCL-3, but it is not apparent why they 
did not see activation with p50. 
An expression plasmid for a mutant BCL-3, lacking the 
unique amino- and carboxy-terminal regions (ABCL-3) 
was constructed. ABCL-3 was expressed in the nucleus 
in L929 cells (data not shown) but failed to superactivate 
with p50 and was even inhibitory to the activation by 
p50 (Fig. 2C). Thus, the amino- and carboxy-terminal 
regions of BCL-3 are needed for coactivation with p50 
and might contain transcriptional ctivation sequences. 
Without these sequences, BCL-3 acts as an inhibitor. 
Association of BCL-3 with p50, which is bound 
to KB motif DNA 
It was reported previously that a bacterially expressed 
polypeptide corresponding to a truncated human BCL-3 
(289 amino acids of the full-length 454 amino acids) 
(Wulczyn et al. 1992), as well as murine BCL-3 produced 
by a baculovirus ystem (Nolan et al. 1993), inhibited 
binding of p50 to KB motif DNA. These results appear 
inconsistent with the trans-activation asdescribed here. 
The amino acid sequences flanking the ankyrin repeat 
are unique, highly conserved between human and 
mouse, and contain multiple potential phosphorylation 
sites that may modify the function of the wild-type pro- 
tein. Therefore, we expressed the full-length mouse 
BCL-3 and ABCL-3 protein in human kidney cell 293 
cells and further tested their properties. Transfection of a 
BCL-3 expression plasmid into 293 cells caused an accu- 
mulation of BCL-3 protein detectable by Western blot- 
ting with anti-BCL-3 rabbit serum {Fig. 3, lane 3). Cells 
transfected with either empty vector or a p50 expression 
plasmid did not accumulate BCL-3 [Fig. 3, lanes 1,21. 
This is in contrast to the observation that overexpressed 
p65 induces an accumulation of its target molecule, 
IKB-~ (Scott et al. 1993). The BCL-3 protein was produced 
as a broad band consisting of multiple species [Fig. 3, 
lanes 3,71. This is likely the result of phosphorylation, 
because phosphatase treatment converted the pattern 
into a nearly homogeneous, faster-migrating species {Fig. 
3, lane 8). In contrast, ABCL-3 was expressed as sharp 
band {-35 kDI, and its mobility was unchanged after 
phosphatase treatment (Fig. 3DI. Thus, it is likely that 
the clustered serine and threonine residues in BCL-3, 
which were removed by truncation, are sites of phosphor- 
ylation. 
The stimulation by BCL-3 in the transfection experi- 
ments suggested that it might bind to pS0 to form a 
ternary complex with DNA. To test this idea, we incu- 
bated NF-KB p50 or p65 proteins with BCL-3 protein and 
a biotinylated KB motif DNA. Resulting complexes were 
purified by streptavidin-agarose column chromatogra- 
phy [Materials and methods). After washing the column 
with five bed volumes of binding buffer, the bound pro- 
Figure 2. Effect of mutated pS0 and BCL-3 on coactivation. (A) Naturally processed p50 can oactivate with BCL-3. L929 cells were 
transfected with 0.5 ~g of p-55IgKLuc, 0.05 ~g of pEVRF105 {a p105 expression vector), and indicated amounts of pCDMBCL3. 
Stimulation by BCL-3 expression plasmid alone (0.12 ~g) was 1.2-fold. (B) An artifically processed long p50 (p50Xba) failed to coactivate 
with BCL-3. L929 cells were transfected with 0.5 p,g of p-55IgKLuc and effectors (0.05 ~g). (1) No effector; (2) pCDM50; {3) pCMV50Xba; 
(4) pRSVp52; (5J pCDMBCL3; (6) pCDM50 + pCDMBCL3; (7) pCMVSOXba + pCDMBCL3; (8) pRSVp52 + pCDMBCL3. (C) A mu- 
tant BCL-3 (ABCL-31 failed to coactivate with p50. L929 cells were transfected with 0.5 ~g of p-55IgKLuc and effectors {0.05 ~g). (1) No 
effector; (2) pCDM50; (3) pCDMBCL3; (4) pCDMABCL3; (5) pCDM50 + pCDMABCL3; (6) pCDM50 + pCDMABCL3. Error bars 
represent 2.E. from quadruplicated transfection trials. 
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Figure 3. Expression ofmouse BCL-3 in human 293 cells. 293 
cells (3 x 10  6 cells) were transfected with expression plasmids 
(10 wg): pCDM8 (1,4); pCDM50 (2,5); pCDMBCL3 (3,6,7,8); and 
pCDMABCL3 (9,10). Cell lysates corresponding to l0 s cells 
were analyzed by SDS-PAGE and Western blotting using anti- 
BCL-3 rabbit serum (A,C,D) or anti-pS0 rabbit serum (B). Ly- 
sates containing BCL-3 and ABCL-3 (7,9) were treated with acid 
phosphatase (1.0 units) prior to SDS-PAGE (8,10). 
teins were eluted, resolved by SDS-PAGE, and analyzed 
by immunoblotting using an anti-BCL-3 antibody (Fig. 
4). BCL-3 did not bind to the KB motif DNA by itself 
(lane 4), but in the presence of (p50)2 it was recovered in 
a complex associated with DNA (lane 6). Ternary com- 
plex formation was observed using both IgK and H-2 KB 
motifs, p65 homodimers or p50/65 heterodimers te ted 
under the same conditions failed to interact with BCL-3, 
although these proteins were efficiently retained on im- 
munoglobulin KB motif DNA, or H-2 KB motif DNA, as 
shown by immunoblotting using anti-p50 and anti-p65 
antibodies (data not shown). These results demonstrate 
that BCL-3 can specifically associate with (p50)2 while 
the homodimer is bound to a KB motif in DNA. 
We attempted to demonstrate he ternary complex by 
mobility shift assay using the same protein preparations 
as in the previous experiment. However, the mobility of 
the p50-DNA complex was identical in the presence or 
absence of BCL-3. Also, our anti-BCL-3 antibody failed to 
affect the mobility of the pS0--DNA complex when 
BCL-3 was added. Presumably BCL-3 dissociates from 
the complex during the electrophoretic analysis. Re- 
cently, Bours et al. (1993) demonstrated significant er- 
nary complex formation composed of p50, BCL-3, and KB 
motif DNA under their EMSA conditions. Interestingly, 
under the same conditions, BCL-3 does not inhibit bind- 
ing of p50 to DNA. This is consistent with our observa- 
tion that mammalian BCL-3 exhibited amoderate inhib- 
itory effect on p50 DNA binding only when > 10x molar 
excess of BCL-3 was added, whereas insect cell-derived 
BCL-3 was clearly highly inhibitory to pS0 DNA binding 
{Nolan et al. 1993; T. Fujita et al., unpubl.). This is pre- 
sumably attributable to the altered modification of pro- 
teins in insect versus mammalian cells (H6ss et al. 1990; 
also see Discussion). 
BCL-3 activates transcription by p50 in vitro 
The above results prompted us to test the function of 
BCL-3 as a transcriptional ctivator in vitro. The 293 
cell-derived BCL-3 and a control extract from mock- 
transfected 293 cells were partially purified by mono Q 
chromatography (Materials and methods}. HeLa cell nu- 
clear extract, which is devoid of detectable amounts of 
p50, p65 (Fujita et al. 1992), and BCL-3 proteins (deter- 
mined by Western blotting; data not shown), was sup- 
plemented with partially purified BCL-3 or a control 
preparation and used for transcription reactions (also free 
of p50 and p65 as shown by immunoblotting; data not 
included). A mixture of a reference template (containing 
only a TATA box) and a test template (containing three 
tandem repeats of a KB motif) were first reacted with 
varying amounts of the NF-KB subunits on ice and then 
transcribed in HeLa cell nuclear extract with or without 
added BCL-3 (Materials and methods). Transcripts were 
detected by primer extension and quantitated using a 
PhosphorImager: Their values were normalized to the 
reference transcript. The IFN-[3 KB motif, shown previ- 
ously to be activated poorly by p50 homodimer in vitro, 
was significantly further activated by the addition of 
BCL-3 (Fig. 5B). Addition of BCL-3 alone (Fig. 5B, ordi- 
nate) did not increase transcription. Transcriptional c- 
tivation by p65 homodimers was not affected by BCL-3 
(Fig. 5A), consistent with the finding that BCL-3 does not 
associate with (p65)2 (Fig. 4). Similarly, activation by 
p50/65 heterodimers was not affected by BGL-3 (Fig. 5C), 
which also failed to interact with p50/65 in vitro (Fig. 4). 
Figure 4. BCL-3 specifically associates withp50 bound 
to KB motif DNA. Insect cell-derived NF-KB subunits (1 
pmole) were mixed with 293 cell-derived BCL-3 (1.2 
pmole), and biotinylated DNA probe containing three 
copies of the KB motif from the IgK gene {1.2-pmole 
sites) was incubated in different combinations. Proteins 
bound to DNA were separated outby streptavidin-aga- 
rose column chromatography. The bound fractions 
were size ffactionated by electrophoresis in SDS, and 
the presence ofBCL-3 was determined by Western blot- 
ting using a rabbit an i-BCL-3 serum. The additions to 
individual samples are indicated. 
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Figure 5. In vitro, BCL-3 activates a KB 
motif-containing promoter synergistically 
with p50. Templates containing three tan- 
dem repeats of the IFN-B KB motif (A,B), 
the IgKB motif (C,D), or the H-2 KB motif 
(E) were first reacted with the indicated 
amounts of purified recombinant p65 (A), 
p50 (B,D,E) or p50/65 (C). The templates 
were then transcribed using HeLa cell nu- 
clear extract supplemented with partially 
purified control fraction {[~) or BCL-3 frac- 
tion (O). Original autoradiographs are 
shown above each panel: Control (bottom 
set) or plus BCL-3 {top set). Primer exten- 
sion products for test transcripts (bottom 
band) and reference transcripts (top band) 
are seen as described pr viously (Fujita et 
al. 1992). The amounts of NF-KB subunits 
added were 0, 74, 220, and 670 fmoles 
(from left to right). 
BCL-3 also augmented p50-dependent transcription on 
immunoglobulin and H-2 KB sites (Fig. 5D, E). Because 
the H-2 KB site is the one activated most efficiently by 
(p50)~, the further stimulation by BCL-3 produced the 
highest level of in vitro activity that we have observed 
using NF-KB-related proteins (Fig. 5E). The two- to three- 
fold activation by BCL-3 was approximately that ob- 
served in vivo (Fig. 2). These in vitro results again con- 
firm that BCL-3 has properties distinct from those of 
IKB-e~, which acts as a strong inhibitor of transcription i  
vitro (Kretzschmar et al. 1992; T. Fujita, G.P. Nolan, 
H.-C. Liou, M.L. Scott, and D. Baltimore, unpubl.). 
Discuss ion  
BCL-3, a transcriptional coactivator 
We find that BCL-3 can be a transcriptional coactivator, 
in direct contrast o the inhibitory function of the related 
IKB-~ protein. In the presence of (p50)2, but not by itself 
or with pS0/p65 or (p65)2, BCL-3 forms a ternary com- 
plex with DNA and stimulates transcription. We also 
find that (p50)2 is itself an activator; BCL-3 superstimu- 
lates its activity by two- to threefold. Transfection ex- 
periments and in vitro analyses give congruent results. 
Recently, Bours et al. (1993) reported similar findings 
that BCL-3 can directly coactivate with p52. 
Our findings with BCL-3 are reminiscent of earlier 
work on the herpes virus coactivator, VP16. That pro- 
tein, too, is inactive alone but binds in a ternary complex 
with Oct-1 and stimulates transcription as a conse- 
quence of a highly acidic trans-activation domain 
(Tanaka et al. 1988). VP16 interacts with both Oct-1 and 
the DNA in the complex; we have no indication that 
BCL-3 interacts with DNA. 
BCL-3 might increase the magnitude of transcription 
by (p50)2 through two mechanisms. First, the proline- 
rich regions in BCL-3 could provide activation domains 
as do those in the CTF/NF-1 and AP-2 factors (Williams 
et al. 1988; Mermod et al. 1989). Our finding that ABCL- 
3, which lacks the proline domains, failed to activate 
may be relevant o this. Second, p50, whose transcrip- 
tional activity is correlated to a specific protease-resis- 
tant conformation i  vitro (Fujita et al. 1992), may be put 
into its active conformation more efficiently as a result 
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of association with BCL-3. These are not mutually ex- 
clusive notions. 
The observation that excess mammalian BCL-3 inhib- 
its DNA binding by (p50)2 (Nolan et al. 1993) suggests 
that the ternary complex is less stable than the p50- 
DNA complex. In vitro transcription results suggest that 
although less stable, this unit can participate in forming 
an active initiation complex resulting in a higher rate of 
transcription. 
Gene regulation by p50 and BCL-3 
Biologically, the individual NF-KB subunits have multi- 
ple specific functions. The classical NF-KB, p50/65, in 
most cell types is a dormant activator, held in the cyto- 
plasm, and in a non-DNA-binding state, by IKB-~ (Bae- 
uerle and Baltimore 1988a, b, 1989; Nolan and Baltimore 
1992). Upon cellular stimulation, the heterodimers are 
released from inhibition and move to the nucleus to ac- 
tively promote specific gene expression (Nolan and Bal- 
timore 1992). The (p50)2 form, and perhaps (p52)2 in 
some cells, detected in the nuclei of many cell types as 
KBF-1 (Isra61 et al. 1987), activates certain KB sites con- 
stitutively and should be subject o coactivation by BCL- 
3. Because the p50 homodimer has an extremely high 
affinity for DNA binding (Kd --5 pM) (Zabel et al. 1991; 
Fujita et al. 1992), as compared with other eukaryotic 
DNA-binding proteins (Kd --10--100 riM)(Chodosh et al. 
1986; Meisterernst et al. 1988; Harada et al. 1989; Cao et 
al. 1991), it might bind effectively to chromosomal DNA 
but not function as a strong activator. The coactivator 
BCL-3 could then easily recognize the bound (p50)2 and 
interact with it. It remains to be demonstrated whether 
BCL-3 can change DNA-binding sequence specificity of 
(p50)2. If this is the case, BCL-3 would participate in a 
more complex form of regulation. IKB-~/(Liou et al. 1992) 
can bind to (p50)2 and act as an inhibitor; how its regu- 
latory properties interact with those of BCL-3 remains to 
be determined. A (p65)2 form can readily be made in vitro 
and may exist in cells. Free (p65)2 can apparently up- 
regulate the synthesis of IKB-a, thus ensuring that it and 
NF-KB are maintained in their inactive state (Scott et al. 
1993). Finally, there are other Rel-related subunits--Rel 
itself, RelB, and the p52 derived from pl00 (NFKB-2)-- 
each of which can interact with the other Rel proteins, 
producing apanoply of potential regulatory interactions. 
Phosphorylation of BCL-3 and regulation 
The activities of BCL-3 differ from those of IKB-~. The 
interaction of IKB-a with (p65)2 and p50/65 heterodimers 
[and even (p50)2, albeit weakly] has two effects: It 
strongly impairs their DNA-binding ability, and it se- 
questers them in the cytoplasm. In short, the activity of 
IKB-a appears to be inhibitory. This may not be the 
whole story, however, because Morin and Gilmore 
(1992) reported that IKB and the carboxy-terminal seg- 
ment of p105 have activation domains as assayed in 
yeast cells. BCL-3 has two activities: one inhibitory and 
the other stimulatory. The inhibitory activity has been 
documented extensively (Franzoso et al. 1992; Wulczyn 
et al. 1992; Kerr et al. 1993; Naumann et al. 1993; Nolan 
et al. 1993): It involves a specific interaction with (p50)2 
or (p52)2 that prevents binding to DNA and even re- 
moves bound (p50)2 from DNA. Franzoso et al. (1992), 
however, have shown that the consequences can be 
stimulatory if the bound (p50)2 is removed from DNA 
and is replaced by p50/p65, which is a stronger activator. 
BCL-3 protein expressed in bacteria or insect cells shows 
the strong DNA-binding inhibitory effect specific to 
(p50)2. 
In vitro, however, mammalian cell-derived BCL-3 
binds to its target molecule, (p50)2, without dissociating 
it from DNA, and the BCL-3/p50 interaction activates 
transcription. The difference between the mammalian 
cell-derived BCL-3 and the inhibitory proteins from bac- 
teria and insect cells could be a result of post-transla- 
tional modification. H6ss et al. (1990) reported that SV40 
large T antigen produced in insect cells is altered in its 
phosphorylation as well as DNA-binding pattern. The 
critical serine residues responsible for binding to site II 
in the SV40 replication origin and down-regulation are 
underphosphorylated. In the case of insect cell-derived 
BCL-3, artificial removal of phosphate residues by phos- 
phatase treatment results in an inactivation of BCL-3 
(Nolan et al. 1993), suggesting that some phosphoryla- 
tion is required for interaction with (p50)2. It is likely 
that the function of BCL-3 protein can be regulated 
through phosphorylation f certain amino acid residues, 
making it a direct activator, an indirect activator, or even 
an inhibitor. If this is so, BCL-3 can play the sophisti- 
cated role of a double agent, depending on the needs of 
developmental processes or environmental conditions. 
In vivo function of BCL-3 
We have limited information about the expression of 
BCL-3 protein in vivo. Its mRNA is expressed in a wide 
variety of tissues and is particularly evident in spleen, 
liver, and lung. In the regenerating liver, a KB site-bind- 
ing factor called posthepatectomy factor (PHF) is highly 
induced without p50/65 induction (Tewari et al. 1992). 
Because PHF is reactive with anti-p50 antibody, BCL-3 
might be involved in the formation of PHF. 
Results that differ from other reports 
Our results differ from those of others, including Bours 
et al. (1992, 1993) and Franzoso et al. (1992), who failed 
to observe gene activation by p50 or synergism by p50 
and BCL-3. One possible explanation for this difference 
is the nature of the p50 proteins used. Our expression 
vector was designed to make 50-kD protein (amino acids 
1-401; Fujita et al. 1992), with an apparent molecular 
mass (by electrophoretic analysis) very similar to the en- 
dogenously processed p50 derived from overexpressed 
p105 in 293 and L929 cells (data not shown). Also, trans- 
fection of a p105 expression plasmid to L929 cells, which 
results in the expression of endogenously processed ma- 
ture p50, showed synergism with BCL-3 (Fig. 2A). Other 
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studies have uti l ized a construct hat should produce a 
signif icantly longer p50 (XbaI truncation, amino acids 
1-503; expected molecular  mass, >60 kD), including 
those studies that failed to see act ivat ion by p50 and 
BCL-3 (Beg et al. 1992; Franzoso et al. 1992). The longer 
p50 is not processed to a proper size in vivo (T. Fujita et 
al., unpubl.) and failed to cooperate with BCL-3 effi- 
c ient ly (Fig. 2B). Cell l ine differences or peculiarit ies of 
the transfection method are unl ike ly  explanations for 
the different results because we found a similar syner- 
gism using the NTera-2 cell l ine that was used by Fran- 
zoso et al. (1992) and fol lowing their protocol (Fig. 2B). 
Because we showed that a reporter gene regulated by the 
HIV LTR was also coactivated by p50 and BCL-3, it is 
unl ike ly  that the reporter used in our other experiments 
is peculiar. In some of the publ ished cotransfections, the 
level of BCL-3 could be inappropriate to reproduce syn- 
ergism with p50 because mammal ian  BCL-3 added in 
excess over p50 can be inhibitory for DNA binding (Fran- 
zoso et al. 1992; T. Fujita et al., unpubl.). 
Mater ia ls  and methods  
Construction of plasmids 
Reporter constructs with or without three tandemly repeated 
KB motifs upstream of a minimal IFN-J3 promoter [-55 to + 19 
(Fujita et al. 1992)] were prepared from pBL, a plasmid contain- 
ing Photonius pyralis luciferase DNA (De Wet et al. 1987) and 
the polyadenylation site from pSV2 (between HindIII and HincII 
sites of pBluescript KS + ). pBL was digested with Sinai and Hin- 
dIII, and the larger fragment was isolated. This fragment and a 
HindIII-SalI fragment (whose SalI end had been blunted) from 
p-55IgKcat (Fujita et al. 1992) were ligated to generate 
p-55IgKLuc, pHIVLTRLuc {originally p22Luc), containing the 
HIV-1 LTR upstream of the luciferase structural gene, was a 
kind gift of Dr. K. Saksela (The Rockefeller University, New 
York). pEVRF105 was constructed by cloning the p105 eDNA 
(Ghosh et al. 1990) into pEVRF1 (Matthias et al. 1989). 
pCDM50, pCDM65, pCDMBCL3, pCDMABCL3, and pCDMIKB 
were constructed by cloning the pS0 eDNA (from pVLp50; Fu- 
jita et al. 1992), the p65 eDNA (from pVLp65; Fujita et al. 1992), 
the mouse BCL-3 eDNA (Nolan et al. 1993), a portion of mouse 
BCL-3 (ABCL-3; spanning amino acids 104-352) and the IKB-a 
eDNA (Liou et al. 1992) into CDM8 {Seed 1987) downstream of
the cytomegalovirus promoter. The p50Xba expression vector, 
pCMV50Xba, was a kind gift of Dr. S. Akira (Tokyo University, 
Japan). pRSVp49 was obtained from C.S. Duckett. 
Luciferase activity assay 
L929 cells were seeded 1 day before transfection (5 x lO s cells/ 
well in 24-well dishes). Transfection was performed by the 
DEAE--dextran protocol (Seed 1987). Total amounts of plasmid 
were kept constant by adding empty vector. After 48 hr, the 
culture medium was removed and cell lysis buffer was added 
(200 ~1; Luciferase Assay System, Promega). A portion of the 
extract (3 ~1) was reacted with luciferase substrate (27 ~1}. The 
luminescence was quantitated by a scintillation counter (Beck- 
man) in the single photon mode. Backgrounds from the sub- 
strate solution and the counter were -30,000 cpm. L929 cells 
transfected with reporter construct alone usually gave 100,000- 
1,000,000 cpm, which was taken as basal activity (onefold). 
NTera cells were transfected asdescribed elsewhere (Bours et al. 
1992). Extracts (500 ~1) were prepared from 3 x 106 cells, and a 
portion (3 ~1) was subjected to luciferase reaction (above). 
Western blotting 
Western blotting was performed using 1 : 1000 diluted rabbit 
polyclonal antisera s primary antibody (Liou et al. 1992) and 
alkaline phosphatase-conjugated goat anti-rabbit antibody as 
secondary reagent. Phosphatase treatment was performed in 0.1 
M MES buffer (pH 6.0). 
BCL-3 production and purification 
293T cells were seeded 24 hr before transfection (3 x 106 cells/ 
5-cm dish). Cells were transfected with pCDMBCL3 by the cal- 
cium phosphate method. Fifteen hours after addition of DNA, 
the cells were washed and incubated further for 33 hr. Whole- 
cell extract was prepared with buffer D' (20 mM HEPES at pH 
7.9, 1 mM EDTA, 1 mM DTT, 10% glycerol, 0.1% NP-40), con- 
taining 400 mM NaC1, by vortexing briefly. The suspension was 
clarified by centrifugation (100,000g for 30 min), and the super- 
natant was diluted with buffer D' to a final NaC1 concentration 
of 50 mM. After removal of insoluble materials by centrifuga- 
tion (lO0,000g for 30 rain), the lysate was applied to an FPLC 
mono Q column. The column was washed with buffer D' con- 
taining 50 mM NaC1, and proteins were eluted by NaC1 gradient 
(50-1000 mM, in the same buffer). BCL-3 was reproducibly 
eluted at -100 mM NaC1 as detected by Western blotting using 
anti-BCL-3 antiserum. Control fractions were prepared identi- 
cally, except pCDMBCL3 DNA was omitted. The control and 
BCL-3 fractions were adjusted to 50 mM NaC1 by addition of 
buffer D'. The control lysate was negative for BCL-3 by Western 
blotting (data not shown). Protein species contained in the par- 
tially purified control and BCL-3 fractions were indistinguish- 
able after SDS-PAGE and Coomasie brilliant blue staining. 
Test for association of KB motif DNA, NF-KB subunits 
and BCL-3 
The probes used were double-stranded DNA oligonucleotides 
containing three tandem repeats of either the IgK or H-2 KB 
motifs {Fujita et al. 1992). The oligonucleotides were annealed, 
and their ends were filled in with Klenow DNA polymerase in
the presence of a trace amount of [32p]dCTP, together with cold 
dCTP, dTTP, dGTP, and biotin-dATP (each 0.2 raM). About 
65% of the probe molecules were biotinylated (32.5% of the 
endsl. Reaction mixtures (50 ~1) containing combinations of
biotinylated KB motif DNA (1.2 pmole), NF-KB subunits (1 
pmole), and 293-cell derived BCL-3 (crude, 1.2 pmole) in buffer 
D' were incubated at 4~ for 10 min and applied to a streptavi- 
din-agarose column (20-~tl bed). The column was washed with 
100 ~tl of buffer D' containing 50 mM NaC1. The bound proteins 
were eluted with SDS-PAGE sample buffer and subjected to 
Western blotting analysis, p50 and p65 homodimers and p50/65 
heterodimers were quantitated by Scatchard analysis using 
known amounts of KB motif DNA as probe. BCL-3 was quanti- 
tated by Western blotting using known amounts of insect cell- 
derived BCL-3 as standards. 
In vitro transcription 
In vitro transcription was performed as described previously, 
except that partially purified control or BCL-3 fraction tthe 
equivalent of 400 fmoles of BCL-3) was added. Test and refer- 
ence transcripts were quantitated asdescribed previously (Fujita 
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et al. 1992). Transcription of test template by unsupplemented 
HeLa cell extract was taken as basal activity (onefold). 
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